Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential new targets for antithrombotic therapy.

A Gruber1, S R Hanson

  • 1Department of Biomedical Engineering at Georgia Institute of Technology & Emory University School of Medicine, Atlanta, Georgia 30322, USA. agruber@emory.edu

Current Pharmaceutical Design
|October 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026
Same author

Simultaneous Probe of the Charm and Bottom Quark Yukawa Couplings Using tt[over ¯]H Events.

Physical review letters·2026
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

New antithrombotic therapies aim to target clot formation without impairing normal hemostasis. Research suggests inhibiting intrinsic coagulation, reducing platelets, or enhancing protein C/thrombolytic pathways could improve safety and efficacy.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombosis, characterized by blood clot formation causing vessel occlusion, poses significant health risks.
  • Current antithrombotic drugs (e.g., heparin, aspirin) target coagulation or platelets but can impair hemostasis, leading to bleeding.
  • Existing treatments often require careful dosing and monitoring, limiting their widespread optimal use.

Purpose of the Study:

  • To explore novel therapeutic targets for antithrombotic therapy.
  • To identify strategies that inhibit thrombosis without compromising essential hemostasis.
  • To guide the development of safer and more effective antithrombotic agents.

Main Methods:

  • Review of existing antithrombotic strategies and their limitations.

Related Experiment Videos

  • Analysis of hemostatic pathways and disorders for potential therapeutic targets.
  • Theoretical considerations and experimental data evaluation for novel approaches.

    • Main Results:

    • Existing antithrombotic drugs have limitations in efficacy and hemostatic safety.
    • Naturally occurring hemostatic disorders offer insights into protective mechanisms against thrombosis.
    • Specific pathways identified for potential therapeutic intervention.

    Conclusions:

    • Inhibiting the intrinsic coagulation pathway is a potential strategy.
    • Reducing circulating platelet count may offer antithrombotic benefits.
    • Enhancing endogenous protein C or thrombolytic pathways could improve antithrombotic therapy safety and efficacy.